Zydus Cadila has received the final approval from the USFDA to market Levofloxacin Injection, 500 mg/20 mL and 750 mg/30 mL (25 mg/mL). Levofloxacin is used in the treatment of bacterial infections and will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
This is significant as it marks the beginning of the approval process for filings made from the Moraiya manufacturing plant after successfully completing the USFDA audit from February 6th to 15th 2017 with Zero 483 observations. The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1674.25 |
| Dr. Reddys Lab | 1235.85 |
| Cipla | 1236.25 |
| Zydus Lifesciences | 941.20 |
| Lupin | 2336.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: